Vol. 3 No. 1 (2014)

Open Access

Articles

Article ID: 123

Clinical Effect analysis on indomethacin suppositories prevention of POST-ERCP acute pancreatitis

by Liang yanqm

Preventive Medicine Research, Vol.3, No.1, 2014; 209 Views, 8 PDF Downloads

ObjectiveToinvestigate the clinical effect of indomethacin suppositories prevention of POST-ERCP acute. Pancreatitis20>Methods180 cases of ERCP were selected from March to September 2015 in ourHospital, all the patients according to the random number table were divided into two groups, there were-cases in the OBsenTation Group and the control group.Hie control group received conventional treatment, the observation group treated with indomethacin on the preventionof the conventional treatment.The serum amylase levels at different time points before and after surgery, acute pancreatitis and hyperamylasemia</b13> author Units:4732b4Nanyang,Henan Zhongnan Industrial Co., Ltd. Staff Hospital surgery oftwo groups were compared.ResultsTheserum amylase levels of the observation group and the control group after 2 H, after H, H PostoperativE were higlier than the preoperative, the degree of elevation of the Obsen T ation Group was smaller than the conTrol Group, the difference was statistically significance (P 0.05).The incidence of acute pancreatitisand hyperamylasemia of the Obsen 7 ation Group were lower than the control groUp, the difference was statistically significant (^ 0.05).conclusionindomethacin can be effective in preventing POST-ERCP acutePancreatitis and reduce the incidence of hyperamylasemia, can significantly lower blood.

Open Access

Articles

Article ID: 154

Observational studies on prophylaxis of hepatitis B virus reactivation with long or short course oralAgents among patients with acute myeloidleukemia

by Zhuang yan

Preventive Medicine Research, Vol.3, No.1, 2014; 159 Views, 2 PDF Downloads

 Background and purpose:hepatitis B virus (HBV) reactivation is one of serious complications among patients with acute myeloid LeukeMia (AML) following cytotoxic induction and consolidation chemotherapy.Nucleoside analogs including lamivudine and entecavir have been widely used as prophylactic or preemptive treatment for HBV reactivation.This study is to investigate clinical efficacy and safety of a long or short course oral ANTI-HBV for agents HBV reactivation in AML patients with HBV infection during chemotherapy.Methods:themedical records AML patients with HBV infection receiving aT least 4 courses of chemotherapy were Fund-funded:Department of theNineth People's Hospital affiliated to Shanghai Jiaotong University Medical School Fusion Fund(yard Fusion2017)Communications Author:LiuYanE-mail:ybb539355@163. com Theretrospectively identified and systematically analyzed.These patients were further divided into four groups according to their hepatitis B surface antigen (HBsAg) status prior to initiation of chemotherapy and duration of prophylactic therapy.Reactivation of HBV and toxicity profiles of oral antiviral agents were systematically analyzed and compared among differeNT groups.Results:HBV reactivation and documented hbv-related hepatitis wereSignificantly lower in AML patients under long course antiviral prophylaxis (i.e. continuing oral antiviral therapy for atLeast 6 months after cessation of chemotherapy, LCP group) than in the patients with short course antiviral (i.e. continuing oral antiviral therapy for one month after cessation of chemotherapy, SCP Group), which was 5.56% (1/18) And0%(0/18) compared with 45.45% (5/11) and 36.36% (4/11) (p=0.018 and p=0.014). There was little difference in the incidence of antiviral resistance between LCP and SCP groups [11.11% (2/18) V5 9.09% (1/11), p>0.05].Furthermore, the rates of HBV reactivation and hbv-related hepatitis were significantly lower in AML patients with PositivE-HBsAg (HBsAg ^0.05 iu/ml) under long course antiviral prophylaxis than in HBsAg positive patients who received short couRSE antiviral agents [8.33% (1/12) and0%(0/12) V5 66.67% (4/6) and 66.67% (4/6), p=0.022 and p=0.005].Meanwhile, there was little difference in the rates of antiviral resistance-LCP and SCP between groups HBsAg amonge patients [8.33% (1/12) V5 16.67% (1/6), p>0.05].In addition, the rates of HBV reactivation and hbv-related hepatitis as so as antiviral resistance were shown to have LiTtle difference in AML patients with negative HBsAg (hbsag<0.05 iu/ml) between LCP and SCP groups.Concerning antiviral agent toxicity, no grade 3-4 toxicity occurred in patients from LCP or SCP group.Conclusion:Long course prophylaxis with oral antiviral agent appears to be an effective and tolerated preventative approach for reducing risks of HBV reactivation and associated events in AML pAtients with positive HBsAg during chemotherapy, which serves as a platform for the design of prospective clinical.

Open Access

Articles

Article ID: 134

CrownPulse,enterruleTherapyafterbranchframeinsidebloodbolt form toã€Pre -Anti-andCare

by Qiu Jay

Preventive Medicine Research, Vol.3, No.1, 2014; 178 Views, 3 PDF Downloads

PercutaneousCoronary InterventionRuleHealing(percutaneo)UScoronaryInterven-TioN,PCI)surgery has become the first choice for clinical diagnosis and treatment of coronary heart diseaseMethod.bracketinsidebloodbolt(stentthrombosis,ST)YesItsextremely serious complication,likenocan intimeIt is found that emergency treatment can result in severe fatalfruit.istherefore liableguardwillmust have full consciousness,and closely observe the changes in the disease to take active precautionsMeasuresApply,effective control